Sarepta Therapeutics, Inc.

SRPT

$142.42

+65.24% (1 year change)

Avg closing price

Price range

Market Cap

$11.2 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

-

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-7.03

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-20.27x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

-

Earnings before interest expenses and taxes in the last quarter.

Employees

743

The number of full time employees.

Revenue & Earnings

Balance Sheet

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

News

IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week

IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week

This week could see up to nine companies price their IPOs. Here is a look at the companies looking to go public this week. Codiak Biosciences: Clinical stage biopharmaceutical Codiak Biosciences (N...

Benzinga Benzinga, 8 days ago
Sarapta up 2% on positive gene therapy data in muscular dystrophy (NASDAQ:SRPT)

Sarapta up 2% on positive gene therapy data in muscular dystrophy (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) perks up 2% premarket on light volume on the heels of updated follow-up data on two of its gene therapy candidates. SRP-

Seeking Alpha Seeking Alpha, 22 days ago
Sarepta Therapeutics, Inc. (SRPT) Presents at Robert W Baird Global Healthcare Broker Conference Call - (Transcript)

Sarepta Therapeutics, Inc. (SRPT) Presents at Robert W Baird Global Healthcare Broker Conference Call - (Transcript)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Robert W Baird Global Healthcare Broker Conference Call September 10, 2020, 14:00 ET Company Participants Ian Estepan - SVP, Corporate Affairs & Chief of St...

Seeking Alpha Seeking Alpha, about 1 month ago